Sona’s next steps: Road to THT Commercialization
Potential future clinical studies to provide multiple valuation catalysts
Study of biopharma company acquisition valuation lifts by lead product development phase
Mean acquisition valuation increase:
- Pre-clinical to Phase I 302%
- Phase I to Phase II 93%
- Phase II to Phase III 158%
- Phase III to approval 40%
Study data cited is not for medical devices or therapies and may not relate directly to other companies or non-biopharma products or therapies.
Bentley Biomedical as Regulatory Affairs Advisor
- April 13, 2023
Sona Nanotech Secures Bentley Biomedical as Regulatory Affairs Advisor for its THT Colorectal Cancer Therapy Development
Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the “Company” or “Sona”) is pleased to announce it has engaged Bentley Biomedical Consulting to advise Sona on all regulatory, pre-clinical and clinical study preparations and oversight. Shepard Bentley, President and Principal Consultant will act as lead consultant to Sona. Bentley Biomedical will be responsible for regulatory strategies leading towards Federal Drug Administration (“FDA”) and Health Canada approvals and clearances. “Shep” has more than 15 years of regulatory affairs advisory experience working with emerging and Fortune 100 companies, having most recently advised on the successful granting of an FDA interventional device exemption (“IDE”) and subsequent 501(k) approval for both a photothermal therapy system and the intravenous injection of nanoparticles.
“I am excited to begin working with Sona on the development of its targeted hyperthermia therapy (THT) and I look forward to working with THT • Lackofstructuralcomplexity developer Len Pagliaro to take it to the next level as the Company develops pre-clinical studies as it prepares to submit for an IDE and eventual clinical trials for this innovative therapy. THT offers the potential for a significant leap forward for colorectal cancer therapy and understanding the opportunities and demands of the regulatory environment will be key to the Company’s near and medium-term success.”
- Shepard Bentley
Other GNRs Applications
Sit egestas luctus ac dolor, porttitor. Massa quam consectetur feugiat maecenas in tellus, eget rhoncus. Elementum est odio.